APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-mediated amyloid nucleation and phosphoinositide-dependent synaptic failure in Alzheimer disease

In APOE4 carriers, the composition of astrocyte-secreted APOE-containing lipid particles becomes enriched in gangliosides (GM1/GM3 ratio elevation) and depleted in phosphatidylinositol (PI). We propose that this altered lipid particle composition reduces neuronal membrane PI(4,5)P2 pools via impaired PI transfer and phospholipid flippase activity. The resulting PI(4,5)P2 deficit simultaneously creates GM1-enriched membrane microdomains that serve as heterogeneous nucleation sites for amyloid-β42 aggregation, while disrupting phosphoinositide-dependent synaptic scaffolding (PSD-95, Homer1) and glutamate receptor trafficking.

In APOE4 carriers, the composition of astrocyte-secreted APOE-containing lipid particles becomes enriched in gangliosides (GM1/GM3 ratio elevation) and depleted in phosphatidylinositol (PI). We propose that this altered lipid particle composition reduces neuronal membrane PI(4,5)P2 pools via impaired PI transfer and phospholipid flippase activity. The resulting PI(4,5)P2 deficit simultaneously creates GM1-enriched membrane microdomains that serve as heterogeneous nucleation sites for amyloid-β42 aggregation, while disrupting phosphoinositide-dependent synaptic scaffolding (PSD-95, Homer1) and glutamate receptor trafficking. This dual mechanism explains why APOE4 is the strongest genetic risk factor: it creates a membrane environment that both accelerates amyloidogenesis and impairs synaptic resilience. Testable predictions include: (1) APOE4 astrocytes secrete lipid particles with <40% of normal PI content; (2) neurons exposed to APOE4 lipid particles show reduced synaptic PI(4,5)P2 and enhanced Aβ42 fibril nucleation rates; (3) restoring PI(4,5)P2 via DAGKα overexpression or PI delivery prevents both amyloid nucleation and synaptic deficits in APOE4-targeted models.